Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ablynx NV stock logo
ABLYF
Ablynx
$50.63
$50.63
$12.50
$55.04
$3.81B1.995,063 shsN/A
bluebird bio, Inc. stock logo
BLUE
bluebird bio
$4.97
$4.68
$3.20
$28.60
$48.67M0.27443,151 shsN/A
China Biologic Products Holdings, Inc. stock logo
CBPO
China Biologic Products
$119.99
$119.23
$99.74
$120.05
$4.72B0.47148,695 shs390,921 shs
Spark Therapeutics Inc stock logo
ONCE
Spark Therapeutics
$0.18
$113.43
$34.53
$114.20
$6.94M2.05891,560 shsN/A
Repligen Corporation stock logo
RGEN
Repligen
$127.36
+0.3%
$127.05
$102.97
$182.52
$7.13B1.11728,834 shs208,766 shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ablynx NV stock logo
ABLYF
Ablynx
0.00%0.00%0.00%0.00%0.00%
bluebird bio, Inc. stock logo
BLUE
bluebird bio
0.00%0.00%+0.20%+1.64%-73.08%
China Biologic Products Holdings, Inc. stock logo
CBPO
China Biologic Products
0.00%0.00%0.00%0.00%0.00%
Spark Therapeutics Inc stock logo
ONCE
Spark Therapeutics
0.00%0.00%0.00%0.00%0.00%
Repligen Corporation stock logo
RGEN
Repligen
+0.41%+2.37%+7.08%+4.32%+5.68%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ablynx NV stock logo
ABLYF
Ablynx
N/AN/AN/AN/AN/AN/AN/AN/A
bluebird bio, Inc. stock logo
BLUE
bluebird bio
2.1147 of 5 stars
3.10.00.00.01.31.71.3
China Biologic Products Holdings, Inc. stock logo
CBPO
China Biologic Products
N/AN/AN/AN/AN/AN/AN/AN/A
Spark Therapeutics Inc stock logo
ONCE
Spark Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Repligen Corporation stock logo
RGEN
Repligen
4.8118 of 5 stars
4.32.00.04.52.91.71.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ablynx NV stock logo
ABLYF
Ablynx
0.00
N/AN/AN/A
bluebird bio, Inc. stock logo
BLUE
bluebird bio
2.25
Hold$44.60797.38% Upside
China Biologic Products Holdings, Inc. stock logo
CBPO
China Biologic Products
0.00
N/AN/AN/A
Spark Therapeutics Inc stock logo
ONCE
Spark Therapeutics
0.00
N/AN/AN/A
Repligen Corporation stock logo
RGEN
Repligen
2.69
Moderate Buy$172.8335.70% Upside

Current Analyst Ratings Breakdown

Latest CBPO, ONCE, BLUE, RGEN, and ABLYF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/24/2025
Repligen Corporation stock logo
RGEN
Repligen
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$150.00
5/5/2025
Repligen Corporation stock logo
RGEN
Repligen
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$180.00 ➝ $180.00
4/30/2025
Repligen Corporation stock logo
RGEN
Repligen
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$202.00 ➝ $189.00
4/29/2025
Repligen Corporation stock logo
RGEN
Repligen
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$200.00 ➝ $190.00
4/29/2025
Repligen Corporation stock logo
RGEN
Repligen
Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradePeer Perform ➝ Outperform$160.00
4/16/2025
Repligen Corporation stock logo
RGEN
Repligen
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$170.00 ➝ $150.00
(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ablynx NV stock logo
ABLYF
Ablynx
$62.73M60.74N/AN/A$2.71 per share18.68
bluebird bio, Inc. stock logo
BLUE
bluebird bio
$103.95M0.47N/AN/A$35.59 per share0.14
China Biologic Products Holdings, Inc. stock logo
CBPO
China Biologic Products
$503.70M9.38$5.01 per share23.93$45.09 per share2.66
Spark Therapeutics Inc stock logo
ONCE
Spark Therapeutics
$64.72M0.11N/AN/A$13.15 per share0.01
Repligen Corporation stock logo
RGEN
Repligen
$634.44M11.28$3.12 per share40.87$35.21 per share3.62
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ablynx NV stock logo
ABLYF
Ablynx
-$122.67MN/A0.00N/AN/AN/AN/AN/A
bluebird bio, Inc. stock logo
BLUE
bluebird bio
-$211.91M-$41.32N/AN/AN/A-565.74%-322.46%-53.17%8/12/2025 (Estimated)
China Biologic Products Holdings, Inc. stock logo
CBPO
China Biologic Products
$138.81M$4.2833.5227.90N/A27.43%8.32%7.64%N/A
Spark Therapeutics Inc stock logo
ONCE
Spark Therapeutics
-$78.82M-$2.11N/AN/AN/A-358.41%-59.10%-33.13%N/A
Repligen Corporation stock logo
RGEN
Repligen
-$25.51M-$0.45N/A53.973.63-3.93%4.53%3.17%7/29/2025 (Estimated)

Latest CBPO, ONCE, BLUE, RGEN, and ABLYF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/29/2025Q2 2025
Repligen Corporation stock logo
RGEN
Repligen
$0.40N/AN/AN/A$174.62 millionN/A
4/29/2025Q1 2025
Repligen Corporation stock logo
RGEN
Repligen
$0.35$0.39+$0.04$0.10$163.65 million$169.17 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ablynx NV stock logo
ABLYF
Ablynx
N/AN/AN/AN/AN/A
bluebird bio, Inc. stock logo
BLUE
bluebird bio
N/AN/AN/AN/AN/A
China Biologic Products Holdings, Inc. stock logo
CBPO
China Biologic Products
N/AN/AN/AN/AN/A
Spark Therapeutics Inc stock logo
ONCE
Spark Therapeutics
N/AN/AN/AN/AN/A
Repligen Corporation stock logo
RGEN
Repligen
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ablynx NV stock logo
ABLYF
Ablynx
N/AN/AN/A
bluebird bio, Inc. stock logo
BLUE
bluebird bio
0.37
0.51
0.33
China Biologic Products Holdings, Inc. stock logo
CBPO
China Biologic Products
N/A
12.01
10.13
Spark Therapeutics Inc stock logo
ONCE
Spark Therapeutics
0.35
4.67
4.35
Repligen Corporation stock logo
RGEN
Repligen
0.27
6.79
5.79

Institutional Ownership

CompanyInstitutional Ownership
Ablynx NV stock logo
ABLYF
Ablynx
N/A
bluebird bio, Inc. stock logo
BLUE
bluebird bio
87.43%
China Biologic Products Holdings, Inc. stock logo
CBPO
China Biologic Products
34.77%
Spark Therapeutics Inc stock logo
ONCE
Spark Therapeutics
88.37%
Repligen Corporation stock logo
RGEN
Repligen
97.64%

Insider Ownership

CompanyInsider Ownership
Ablynx NV stock logo
ABLYF
Ablynx
N/A
bluebird bio, Inc. stock logo
BLUE
bluebird bio
1.40%
China Biologic Products Holdings, Inc. stock logo
CBPO
China Biologic Products
2.73%
Spark Therapeutics Inc stock logo
ONCE
Spark Therapeutics
6.00%
Repligen Corporation stock logo
RGEN
Repligen
1.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ablynx NV stock logo
ABLYF
Ablynx
N/A75.25 millionN/ANot Optionable
bluebird bio, Inc. stock logo
BLUE
bluebird bio
5209.79 million9.59 millionOptionable
China Biologic Products Holdings, Inc. stock logo
CBPO
China Biologic Products
2,26939.36 millionN/AOptionable
Spark Therapeutics Inc stock logo
ONCE
Spark Therapeutics
36838.52 millionN/ANo Data
Repligen Corporation stock logo
RGEN
Repligen
1,77856.18 million55.51 millionOptionable

Recent News About These Companies

Repligen (NASDAQ:RGEN) Downgraded by Wall Street Zen to "Hold"
Repligen (NASDAQ:RGEN) Coverage Initiated at Barclays
Does Repligen Corp (RGEN) Have a Strong Pricing Power?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Ablynx stock logo

Ablynx OTCMKTS:ABLYF

$50.63 0.00 (0.00%)
As of 04/30/2019

Ablynx NV, a late-stage clinical biopharmaceutical company, develops treatments for a range of therapeutic indications. The company develops Nanobodies that are proprietary therapeutic proteins based on single-domain antibody fragments for the treatment of inflammation, hematology, immuno-oncology, oncology, and respiratory diseases. Its clinical programs include caplacizumab, an anti-von Willebrand Factor Nanobody that has completed Phase III clinical trial to treat acquired thrombotic thrombocytopenic purpura; ALX-0171, which is in Phase IIb clinical trial for the treatment of respiratory syncytial virus infection; and Vobarilizumab, an anti-IL-6R Nanobody that has completed Phase IIb clinical trial for the treatment of rheumatoid arthritis, as well as in Phase II clinical trial to treat systemic lupus erythematosus. The company also develops ALX-0761, which is in Phase Ib clinical trial for the treatment of psoriasis, as well as various auto-immune disorders; Anti-VEGF/Ang2 Nanobody that is in Phase I clinical trial for patients with solid tumors; Anti-CX3CR1 Nanobody, which is in Phase I clinical trial for treating chronic kidney diseases; ozoralizumab, which has completed Phase I/IIa clinical trial for the treatment of auto-immune disorders with focus on rheumatoid arthritis; and ALX-0141, a trivalent Nanobody for the treatment of bone-loss related disorders comprising osteoporosis and bone metastasis, as well as completed a Phase I study in post-menopausal women. Ablynx NV has collaboration and alliance agreements with Merck & Co., Inc., AbbVie, Inc., Boehringer Ingelheim International GmbH, Merck KGaA, Eddingpharm, Novo Nordisk A/S, Novartis Pharma AG, Taisho Pharmaceutical Co., Ltd., and Sanofi S.A. The company was formerly known as MatchX and changed its name to Ablynx NV in June 2002. Ablynx NV was founded in 2001 and is headquartered in Ghent, Belgium.

bluebird bio stock logo

bluebird bio NASDAQ:BLUE

$4.97 0.00 (0.00%)
As of 06/2/2025

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

China Biologic Products stock logo

China Biologic Products NASDAQ:CBPO

China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also provides human immunoglobulin and IVIG for original and secondary immunoglobulin deficiency, auto-immune deficiency, and immunoglobulin G secondary deficiency; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus. In addition, it offers placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; factor VIII for treating coagulopathies; human fibrinogen; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing Human fibrinogen for the treatment for lack of fibrinogen and increase human fibrinogen concentration; and artificial dura and spinal dura mater products for use in brain and spinal surgeries. The company sells its products directly, as well as through distributors. The company was formerly known as China Biologic Products, Inc. and changed its name to China Biologic Products Holdings, Inc. in July 2017. China Biologic Products Holdings, Inc. is headquartered in Beijing, the People's Republic of China.

Spark Therapeutics stock logo

Spark Therapeutics NASDAQ:ONCE

Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells. The company's gene therapy product candidates comprise SPK-8011 and SPK-8016 for hemophilia; SPK-7001 for choroideremia; and SPK-9001 for hemophilia B. It is also developing other liver-directed gene therapies, including SPK-3006 for Pompe disease; and neurodegenerative disease product candidates to address Huntington's disease and others, as well as TPP1 deficiency, which is a form of Batten disease. The company's preclinical programs targets inherited retinal diseases, including Stargardt's disease. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B. It also has licensing and commercialization agreement with Novartis to develop and commercialize voretigene neparvovec outside the United States. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania.

Repligen stock logo

Repligen NASDAQ:RGEN

$127.36 +0.40 (+0.32%)
Closing price 01:10 PM Eastern
Extended Trading
$127.36 0.00 (0.00%)
As of 04:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.